Mr. Speaker, perhaps the member does not have an issue with what I am saying, but I think he should talk to the PBO.
The member for Vancouver Kingsway initiated a study on the new CUSMA with the PBO, and when the report came back, the PBO estimated that the increased drug costs would be $169 million in the first year alone.
I would encourage the member to look at that report from the PBO. I thank the PBO for the work that they have done throughout this Parliament. Certainly they have shone a light on things that the Liberal government does not want Canadians to know or understand. I would encourage the member to go and read that study. I would encourage Canadians to do the same.
I would say that the pharmaceutical manufacturing capacity in Canada is operated by the generic pharmaceutical industry, and there are about 11,000 Canadians who work in the industry. However, the true question is, if we could remove that regressive provision—because the member is saying, “Do not worry; it is not going to impact us”—as they are attempting to do in the U.S., would the Liberals not support that? That is the true question.